Nachrichten zur Viridian Therapeutics Inc. Aktie

Viridian Therapeutics: Fortschritte in der TED-Pipeline stützen Analysten-Kursziele von bis zu 43 USD!

Die Wall Street reagiert mit deutlichen Kurszielanhebungen auf die operativen Entwicklungen bei Viridian Therapeutics. Im Zentrum des Interesses stehen die…

Viridian Therapeutics, Inc. (VRDN) Discusses FDA Approval and Launch Plans for Lumvoa as a New Therapy for Thyroid Eye Disease Transcript

…

Viridian Therapeutics: A Two-Step TED Franchise With More Leverage Than The Market Appreciates

…

Viridian Therapeutics, Inc. (VRDN) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript

…

Viridian Therapeutics, Inc. (VRDN) Discusses Positive Top Line Results From REVEAL-2 Phase III Trial in Chronic Thyroid Eye Disease - Slideshow

…

Viridian Therapeutics stock surges on positive trial results

Viridian Therapeutics stock surges on positive trial results…

Viridian Therapeutics stock tumbles after Amgen Tepezza data

Viridian Therapeutics stock tumbles after Amgen Tepezza data…

Viridian Therapeutics, Inc. (VRDN) Discusses Positive Topline Results from Elegrobart REVEAL-1 Phase III Trial in Active Thyroid Eye Disease Transcript

…

Viridian Therapeutics shares fall over 30% after trial data disappoints

Shares of Viridian Therapeutics (NASDAQ:VRDN) fell more than 30% Monday morning following the release of topline results from the company’s…

Viridian Therapeutics stock tumbles despite trial success

Viridian Therapeutics stock tumbles despite trial success…

Viridian Therapeutics: The Song Remains The Same

…

Viridian Therapeutics (VRDN): Stifel sieht 198 % Kurspotenzial - Überzeugende Langzeitdaten aus der Phase-3-Studie THRIVE!

Viridian Therapeutics (VRDN) hat am 20. Mai 2025 positive Langzeitdaten aus der Phase-3-Studie THRIVE veröffentlicht, die den Wirkstoff Veligrotug bei…

Viridian Therapeutics: Veligrotug De-Risked In TED With Hints Of Differentiation

…

Viridian Therapeutics: A Clearer Picture Emerges (Rating Upgrade)

…

Viridian Therapeutics Superior Prospects Make It A Buy

…

Viridian Therapeutics slides on pricing $225M securities offering

…

Viridian Therapeutics, Inc. (VRDN) Q1 2024 Earnings Call Transcript

…

dpa-AFX ProFeed